UBS Group’s Aquestive Therapeutics AQST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.91M | Sell |
458,414
-5,793
| -1% | -$24.4K | ﹤0.01% | 5145 |
|
|
2026
Q1 | $1.93M | Buy |
464,207
+167,762
| +57% | +$681K | ﹤0.01% | 5009 |
|
|
2025
Q4 | $1.92M | Sell |
296,445
-202,591
| -41% | -$1.26M | ﹤0.01% | 5018 |
|
|
2025
Q3 | $2.79M | Buy |
499,036
+137,772
| +38% | +$596K | ﹤0.01% | 4649 |
|
|
2025
Q2 | $1.2M | Buy |
361,264
+46,935
| +15% | +$135K | ﹤0.01% | 5287 |
|
|
2025
Q1 | $912K | Sell |
314,329
-106,234
| -25% | -$322K | ﹤0.01% | 5360 |
|
|
2024
Q4 | $1.5M | Buy |
420,563
+329,874
| +364% | +$1.52M | ﹤0.01% | 4985 |
|
|
2024
Q3 | $452K | Buy |
90,689
+63,651
| +235% | +$248K | ﹤0.01% | 5301 |
|
|
2024
Q2 | $70.3K | Buy |
27,038
+25,038
| +1,252% | +$83.6K | ﹤0.01% | 6426 |
|
|
2024
Q1 | $8.52K | Sell |
2,000
-290
| -13% | -$965 | ﹤0.01% | 7327 |
|
|
2023
Q4 | $4.63K | Buy |
+2,290
| New | +$4.05K | ﹤0.01% | 7841 |
|
|
2023
Q2 | – | Sell |
-3,744
| Closed | -$4.27K | – | 8871 |
|
|
2023
Q1 | $4.27K | Buy |
+3,744
| New | +$3.25K | ﹤0.01% | 8210 |
|
|
2022
Q4 | – | Sell |
-9,068
| Closed | -$11K | – | 10705 |
|
|
2022
Q3 | $11K | Buy |
9,068
+8,653
| +2,085% | +$9.78K | ﹤0.01% | 8272 |
|
|
2022
Q2 | $0 | Sell |
415
-414
| -50% | -$551 | ﹤0.01% | 10276 |
|
|
2022
Q1 | $2K | Sell |
829
-1,130
| -58% | -$3.3K | ﹤0.01% | 9602 |
|
|
2021
Q4 | $8K | Sell |
1,959
-8,041
| -80% | -$40.4K | ﹤0.01% | 9013 |
|
|
2021
Q3 | $44K | Sell |
10,000
-4,060
| -29% | -$15.9K | ﹤0.01% | 6431 |
|
|
2021
Q2 | $56K | Sell |
14,060
-114
| -0.8% | -$455 | ﹤0.01% | 6324 |
|
|
2021
Q1 | $74K | Sell |
14,174
-9,595
| -40% | -$51K | ﹤0.01% | 6191 |
|
|
2020
Q4 | $128K | Buy |
23,769
+9,669
| +69% | +$57.9K | ﹤0.01% | 5526 |
|
|
2020
Q3 | $68K | Sell |
14,100
-23,981
| -63% | -$157K | ﹤0.01% | 5426 |
|
|
2020
Q2 | $185K | Buy |
38,081
+18,893
| +98% | +$87K | ﹤0.01% | 4856 |
|
|
2020
Q1 | $42K | Buy |
19,188
+9,188
| +92% | +$34.9K | ﹤0.01% | 5963 |
|
|
2019
Q4 | $58K | Hold |
10,000
| – | – | ﹤0.01% | 6264 |
|
|
2019
Q3 | $32K | Hold |
10,000
| – | – | ﹤0.01% | 6446 |
|
|
2019
Q2 | $42K | Sell |
10,000
-3,322
| -25% | -$17K | ﹤0.01% | 6062 |
|
|
2019
Q1 | $92K | Buy |
+13,322
| New | +$93.3K | ﹤0.01% | 5127 |
|
|
2018
Q4 | – | Sell |
-1,325
| Closed | -$23K | – | 8007 |
|
|
2018
Q3 | $23K | Buy |
+1,325
| New | +$21.8K | ﹤0.01% | 6717 |
|
Other funds holding AQST
BCM
RI
SB
SCM
UBS Group's AQST Position: Q2 2026 in Review
UBS Group reduced its Aquestive Therapeutics (AQST) stake by 1.2% in Q2 2026, selling an estimated $24.4K and leaving 458,414 shares worth $1.91M. The position accounts for ﹤0.01% of the portfolio, ranked #5145.
UBS Group first reported a position in AQST in Q3 2018 and has held it in 28 quarters since. The position peaked at $2.79M in Q3 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.
- UBS Group held 458,414 shares of Aquestive Therapeutics worth $1.91M as of Q2 2026.
- UBS Group sold 5,793 Aquestive Therapeutics shares in Q2 2026, an estimated $24.4K.
- Aquestive Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5145 holding.
- UBS Group first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 28 quarters since.
- UBS Group's Aquestive Therapeutics position peaked at $2.79M in Q3 2025.
- 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.